Product Description
AMG 256 (anti-PD-1 x IL21 mutein) is a targeted IL-21 receptor agonist designed to selectively turn on the Interleukin 21 (IL-21) pathway in programmed cell death-1 (PD-1) positive cells. It is being investigated for the treatment of solid tumors.
Mechanisms of Action: PD-1 Inhibitor,IL12 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Spain, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT04362748 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2023-09-21 |
48% |